Leaders in Pulmonary Hypertension
NEIL DAVIE, Ph.D.
HEAD, LATE DEVELOPMENT
CARDIOVASCULAR, METABOLISM & PULMONARY HYPERTENSION
Neil Davie, Ph.D. is the Head, Late Development, of Cardiovascular, Metabolism, & Pulmonary Hypertension (CVM & PH). He has extensive experience as a drug developer leading projects across multiple therapeutic areas, particularly in specialty/rare diseases with high unmet medical need.
Neil joined Janssen in 2019 and is responsible for research and development within the Janssen PH portfolio. This includes drug discovery and external innovation.
Prior to joining Janssen, Neil worked at UCB Pharma as Development Lead. He also spent five years at Bayer as VP of Clinical Development.
Neil obtained his Bachelor of Science in Human Biology from the University of Leeds and his Ph.D. in Pulmonary Pharmacology from Imperial College London. He completed a post-doctoral fellowship at the University of Colorado Health Sciences center (Stenmark Lab), in the field of pulmonary hypertension.
He was appointed Assistant Professor of Pediatric Cardiology at the Children’s Hospital in Denver, working in the pulmonary hypertension lab of Dunbar Ivy.
Neil Davie, Ph.D.
Head, Late Development
Cardiovascular, Metabolism & Pulmonary Hypertension
WORLDWIDE VICE PRESIDENT
CARDIOVASCULAR, METABOLISM AND PULMONARY HYPERTENSION
JANSSEN GLOBAL COMMERCIAL STRATEGY ORGANIZATION (GCSO)
Emmanuelle Quilès is Worldwide Vice President, Cardiovascular, Metabolism and Pulmonary Hypertension. In this role, working closely with R&D, Emmanuelle is focusing on maximizing the value of Janssen’s Cardiovascular & Metabolism (CVM) and Pulmonary Hypertension (PH) pipelines and marketed assets.
Emmanuelle joined Johnson & Johnson as Managing Director of Janssen France in January 2015. She was President of the Janssen Horizon Endowment Fund, member of the LEEM Board of Directors and Vice-President of the Agipharm Board, which brings together the American pharmaceutical companies.
Since 2019, she has also been a member of the GIP Génopole's Industry Science Innovation Committee, the President of the “Artificial Intelligence and Heath” program within the Strategic Committee for Health Industries and Technologies and a member of Business France Board.
Emmanuelle began her career as a clinical research associate first at Rhône-Poulenc, then at Pierre Fabre and then at Genetics Institute until Wyeth bought the company. She then held marketing positions in the Hemophilia field, an area previously unknown to her new employer.
After a successful period in this therapeutic area, she developed into increasingly important roles in various fields (anti-infectives, oncology, neurology) until she was appointed head of Wyeth's largest franchise, the Rheumatology and Dermatology Business Unit.
In November 2007, Emmanuelle was appointed CEO of Wyeth France, and, after Pfizer's acquisition, she was confirmed as President of Pfizer France, the world leader in the pharmaceutical industry.
In December 2012, she left Pfizer to set up Harmonium, a European start-up specialized in diabetology.
Emmanuelle holds a Degree of Biotechnological Engineer from Strasbourg University. She is a Knight of the Legion of Honor.